Piper Jaffray analyst, Charles Duncan, noted Inovio Pharmaceuticals' (NASDAQ: INO) recent progress in infectious disease and is anticipating increased visibility ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE